

MICROBIO WELCOMES RAFFAELLA GIARDINO TO THE TEAM

Brisbane, Australia, 14 December 2021: International medical device and pharmaceuticals consultant Dr Raffaella Giardino has joined the team at scale-up biotech company Microbio to drive commercialisation of the product suite in Europe.

Dr Giardino has spent more than 25 years in the medical diagnostics space, and provides a wealth of knowledge and experience to the Microbio team as it commercialises its InfectID-Blood Stream Infection and InfectID-COVID-19 diagnostic tests.

Based in Lyon, France, Dr Giardino has extensive Executive-level experience in highly-regulated in vitro diagnostics (IVD), medical devices, and pharmaceuticals markets.

Dr Giardino's experience has been focused on commercialisation of new products and growth of existing product sales.

"Having spent years working in France, the UK, USA, Denmark, and Italy, I am excited to work with Microbio to commercialise this exciting product suite," said Dr Giardino.

Based in Brisbane, Microbio is growing its team internationally, helping to deliver its game-changing new technology.

For more information, visit microbio.com.au/about

-Ends-

For media enquiries contact:

Nicole Panoutsos | Wrights | +61 423 506 714 | npanoutsos@wrights.com.au

About Microbio

Microbio is an Australian biotechnology company based in Brisbane. The team at Microbio has brought together the latest advances in bioinformatics, genomics and molecular microbiology to develop a unique and revolutionary pathogen detection test. The Microbio team is working tirelessly to deliver their game-changing new test to the millions of patients who will benefit from better pathogen diagnosis. Microbio is actively seeking partners worldwide, especially in population health and virology, who will integrate this new information into their proactive regional and corporate testing protocols. Additionally, Microbio is looking to work with pathology laboratory partners who can help deliver these highly specific results faster and to remote locations to improve health, regardless of a patient's location.

About InfectID®

InfectID® is a diagnostic technology that detects and identifies bacterial, fungal, and viral targets. The test targets Single Nucleotide Polymorphisms (SNPs), the pathogen's DNA 'fingerprint', found at a specific point in each pathogen's genetic code. By focusing on SNPs rather than the whole genome, the process is fast, inexpensive, highly sensitive and can be adapted to target different pathogens. The technology was refined and became the foundation of Microbio's core InfectID®-Blood Stream Infection (which is currently in development) InfectID®-Blood Stream Infection uses real-time Polymerase Chain Reaction (PCR) to identify Sepsis-causing pathogen species directly from whole blood without the need for pre-culture. Because the technology is suitable for detecting viruses, the company pivoted in 2020 to develop SARS-CoV-2 detection tests.

Microbio Founders

Dr Flavia Huygens | Executive Director, Founder and Chief Scientific Officer

Flavia's 30-year teaching and research career has focused on molecular microbiology, with a particular focus on human pathogens. Flavia's expertise and exceptional ability to bring together emerging technology in molecular microbiology, genomics, proteomics and bioinformatics have culminated in the creation of InfectID. Flavia recently received a DMTC Ltd 2020 Excellence Award in recognition of exemplary professional conduct in support of DMTC's objectives.

Paul Carboon | Executive Director, Founder and Chief Executive Officer

Paul has 25 years of commercialisation experience. In the technology sector, Paul brings deep understanding of commercial and product management as well as product development. Paul is a leader in biotechnology innovation. He currently serves on the AusMedtech national advisory group and is a founding adviser with the BridgeTech Program. Paul is also an Honorary Fellow of Biotechnology at Melbourne University and has been a judge for the prestigious Eureka awards.